Activist DOMA Escalates Proxy Fight, Urges Pacira Sale Amid 'Existential' Patent Risk
PCRX sits 25% above its 52-week low of $18.8.
Summary
Activist investor DOMA Perpetual Capital Management has released definitive additional proxy materials, criticizing Pacira's management for underperformance and patent risk, and pushing for a strategic sale of the company.
Key Events · Ownership and Investor Activity · PCRX
-
Activist Escalates Proxy Battle
DOMA Perpetual Capital Management, a 7.5% shareholder, filed definitive additional proxy materials, intensifying its campaign to elect three director nominees at the upcoming June 9, 2026 annual meeting.
-
Accusations of Underperformance
DOMA alleges 'gross and persistent underperformance' by current management and the board, citing significant negative total shareholder returns over multiple periods, including -64% over five years and -28% since the current CEO took over.
-
Concerns Over EXPAREL Patent Risk
The activist investor claims the board is 'grossly mismanaging' the patent risk for EXPAREL, Pacira's core asset, and warns that further legal losses could be 'catastrophic' without a clear contingency plan.
-
Call for Strategic Alternatives and Sale
DOMA advocates for a board-supervised process to explore strategic alternatives, including a potential sale of the company, as the 'best, safest path' to protect and generate shareholder value.
Analysis · PCRX · Life Sciences
Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake, has intensified its proxy battle by issuing a letter to shareholders. DOMA accuses current management and the board of persistent underperformance and gross negligence in managing the critical EXPAREL patent risk, which they argue poses an existential threat to the company. They advocate for a strategic review, including a potential sale, to protect shareholder value, directly challenging the company's current strategy and executive compensation. This filing is a critical escalation ahead of the June 9, 2026 annual meeting, where shareholders will vote on DOMA's director nominees.
At the time of this filing, PCRX was trading at $23.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $923.6M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.